Skip to main navigation Skip to search Skip to main content

Determinants of pancreatic tropism in metastatic renal cell carcinoma

  • Haitao Xu
  • , Payal Kapur
  • , Alana Christie
  • , Aleksandra W. Nielsen
  • , Averi Perny
  • , Olivia Brandenburg
  • , Charlotte Small
  • , Jeffrey Miyata
  • , Hua Zhong
  • , Courtney Roberts
  • , Roy Elias
  • , Vanina Tcheuyap
  • , Cassandra Duarte
  • , Adrie van Bokhoven
  • , Justine Panian
  • , Haoran Li
  • , Katharine A. Collier
  • , Debra Zynger
  • , Luis Meza
  • , Benoit Beuselinck
  • Neeraj Agarwal, Amir Mortazavi, Sumanta Pal, Rana McKay, Elaine T. Lam, Satwik Rajaram, James Brugarolas

Research output: Contribution to journal › Article › peer-review

Abstract

BACKGROUND. Clear cell renal cell carcinoma (ccRCC) with pancreatic metastases (PM) is paradoxically associated with prolonged overall survival (OS), but the biological basis for this observation remains unclear. METHODS. We analyzed matched primary and metastatic samples from an international consortium of patients with PM (n = 108) and compared them with a previously characterized ccRCC cohort without PM (n = 273). RESULTS. Primary ccRCC tumors associated with PM were dominated by indolent, angiogenic phenotypes, characterized by low-grade histology and reduced mTORC1 activation (all P < 0.001). Tumors of patients with PM were often PBRM1-deficient (80.4% vs. 54.8%, P < 0.001) and rarely harbored BAP1 loss (3.7% vs. 20.7%, P < 0.001). After metastasis diagnosis, patients with PM had significantly longer median OS compared with those without PM (110 vs. 33 months, HR 0.28 [95% CI, 0.19–0.39], P < 0.001). Survival was further prolonged among patients with PBRM1 loss (143 vs. 64 months, HR 0.41 [95% CI, 0.22–0.81], P = 0.008). Notably, PM lesions were typically low-grade and PBRM1-deficient even when more aggressive and evolved clones were present in primary tumors. Finally, PBRM1 loss was associated with preferential response to angiogenesis inhibitors over immune-oncology therapy, reflected by longer time on treatment (32.1 vs. 9.1 months, HR 0.16 [95% CI, 0.06–0.39], P < 0.001). CONCLUSION. These findings illustrate selective tropism of indolent, less-evolved, PBRM1-deficient ccRCC clones for pancreatic dissemination. This biological bias likely underlies therapeutic sensitivity and favorable survival, supporting the consideration of PBRM1 status and metastatic tropism in risk stratification and treatment selection.

Original languageEnglish
Article numbere195195
Pages (from-to)1-21
Number of pages21
JournalJCI Insight
Volume11
Issue number5
DOIs
StatePublished - 2026

Fingerprint

Dive into the research topics of 'Determinants of pancreatic tropism in metastatic renal cell carcinoma'. Together they form a unique fingerprint.

Cite this